Med. praxi. 2016;13(4):168-170 | DOI: 10.36290/med.2016.036

Novelty in treatment of Type 2 diabetes by oral antidiabetic drugs

MUDr.Jan Škrha jr.
III. interní klinika 1. LF UK a VFN

The paper highlights basic principles and novelty in treatment of Type 2 diabetes mellitus. Individualization of diabetes therapy

is emphasized, both in oral antidiabetic drugs selection, and in reaching of individual targets of diabetes control.

Keywords: type 2 diabetes, gliflozins, gliptins, incretins

Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Novelty in treatment of Type 2 diabetes by oral antidiabetic drugs. Med. praxi. 2016;13(4):168-170. doi: 10.36290/med.2016.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. Curr Atheroscler Rep 2016; 18: 16. Go to original source... Go to PubMed...
    2. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242. Go to original source... Go to PubMed...
    3. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335. Go to original source... Go to PubMed...
    4. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. Go to original source...
    5. Williams JA. GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies. Pancreatology 2016; 16(1): 2-7. Go to original source... Go to PubMed...
    6. Zinman B, Wanner Ch, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128. Go to original source...
    7. Doporučený postup péče o diabetes mellitus 2. typu. Doporučení České diabetologické společnosti ČLS JEP. Diabetologie, metabolismus, endokrinologie, výživa 2016, 19(2), 1-9.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.